A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

NCT06876662 · tracked via the Priya Life Science UK tracker

Sponsor

Eli Lilly and Company

Phase

Phase 4

Started

2025-05-20

Last updated

2026-03-02

Condition(s) studied

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Investigational drug(s) / intervention(s)

Pirtobrutinib

Pirtobrutinib: Administered orally.

Study summary

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are: * receiving study intervention * in the short-term follow-up period, or * in the long-term follow-up period Exclusion Criteria: * Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

Primary outcome measure(s)

Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs) — Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier

Trial sites (36)

Facility	City	Region	Status
Sylvester Comprehensive Cancer Center	Miami	Florida	Recruiting
Florida Cancer Specialists	Sarasota	Florida	Recruiting
The Emory Clinic	Atlanta	Georgia	Recruiting
Northwestern University	Chicago	Illinois	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	Recruiting
Mayo Clinic- Minnesota	Rochester	Minnesota	Recruiting
University Of Nebraska Medical Center	Omaha	Nebraska	Recruiting
Cayuga Cancer Center	Ithaca	New York	Active Not Recruiting
Northwell Health	Lake Success	New York	Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York	New York	New York	Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York	New York	New York	Active Not Recruiting
Duke University Medical Center	Durham	North Carolina	Recruiting
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	Recruiting
University of Pennsylvania Hospital	Philadelphia	Pennsylvania	Recruiting
Tennessee Oncology	Nashville	Tennessee	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	Recruiting
Swedish Cancer Institute	Seattle	Washington	Recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	Recruiting
Flinders Medical Centre	Adelaide	Australia	Recruiting
Peter MacCallum Cancer Centre	Melbourne	Australia	Completed
Linear Clinical Research	Victoria	Australia	Active Not Recruiting
CHU de Nantes - Hotel Dieu	Nantes	France	Recruiting
IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi	Bologna	Italy	Completed
Ospedale San Raffaele	Milan	Italy	Recruiting
Nagoya Medical Center	Aichi-Ken	Japan	Active Not Recruiting
National Cancer Center Hospital	Cho-ku	Japan	Completed
National Hospital Organization Kyushu Cancer Center	Fukuoka	Japan	Active Not Recruiting
Tokai University Hospital- Isehara Campus	Isehara	Japan	Active Not Recruiting
Tohoku University Hospital	Miyagi-Ken	Japan	Active Not Recruiting
Hokkaido University Hospital	Sapporo	Japan	Active Not Recruiting
Pratia MCM Krakow	Krakow	Poland	Recruiting
Instytut Hermatologii I Transfuzjologii	Warsaw	Poland	Recruiting
Seoul National University Hospital	Seoul	South Korea	Recruiting
St James's University Hospital	Leeds	United Kingdom	Recruiting
Churchill Hospital	Oxford	United Kingdom	Recruiting
Derriford Hospital	Plymouth	United Kingdom	Recruiting

More Eli Lilly and Company trials in the UK

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants Recruiting

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) Recruiting

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Active, not recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Active, not recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Recruiting

Other trials for the same condition

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies Recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL Active, not recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06876662 on ClinicalTrials.gov ↗ ← All trials in the UK